Exact Sciences CORP DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Exact Sciences Corporation's Board unanimously recommends stockholders vote FOR the proposed merger with Abbott at the upcoming Special Meeting on February 20, 2026.
Exact Sciences Corporation will be acquired by Abbott Laboratories for $105.00 per share in cash, representing a significant premium to recent trading prices.
Exact Sciences Corporation accelerates 2025 annual bonuses and equity awards for its named executive officers to mitigate tax impacts related to its pending merger with Abbott Laboratories.
Exact Sciences announces its planned acquisition by global healthcare leader Abbott, expected to close in Q2 2026, with a per-share value of $105.
Exact Sciences announced an agreement to be acquired by Abbott, a move expected to close in Q2 2026, aiming to expand patient reach and accelerate cancer diagnostics.
Exact Sciences CEO Kevin Conroy discusses the strategic benefits of the proposed acquisition by Abbott Laboratories, emphasizing global reach and shared values.
Exact Sciences Corporation has filed definitive additional materials with the SEC regarding its proposed acquisition by Abbott Laboratories, urging stockholders to review the proxy statement.
Exact Sciences Corporation announced its agreement to be acquired by global healthcare leader Abbott, with the transaction expected to close in the second quarter of 2026.
Exact Sciences announced an agreement to be acquired by Abbott for $23 billion, forming the foundation of Abbott's future in cancer diagnostics and genetics.
Exact Sciences Corporation announced its acquisition by Abbott Laboratories for $23 billion, aiming to create a leading global cancer diagnostics provider.
Abbott Laboratories announced a definitive agreement to acquire Exact Sciences for approximately $21 billion in cash, expanding its presence in cancer diagnostics.
Exact Sciences Corporation has filed a definitive proxy statement with the SEC.
Exact Sciences is building on its 2024 momentum by advancing its mission to eradicate cancer through innovative tests and strategic healthcare provider partnerships.
Exact Sciences Corporation has filed a definitive proxy statement with the SEC.
DEF 14A: Exact Sciences Aims to Eradicate Cancer: Board Seeks Shareholder Support at 2024 Annual Meeting
Exact Sciences' proxy statement highlights the company's mission to eradicate cancer through prevention, early detection, and personalized treatment, alongside key proposals for shareholder voting at the upcoming annual meeting.